

FOI 2862

21st January 2025**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

Question 1

How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

Response:

- Adalimumab – Humira - 33
- Adalimumab Biosimilar - 298
- Apremilast - 0
- Bimekizumab - 15
- Brodalumab - 6
- Certolizumab - 6
- Deucravacitinib – 0
- Dimethyl fumarate – 0
- Etanercept – Enbrel - 0
- Etanercept Biosimilar - 2
- Guselkumab - 66
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 9
- Ixekizumab - 104
- Risankizumab - 86
- Secukinumab - 43
- Tildrakizumab - 6
- Ustekinumab - 25
- Ustekinumab Biosimilar - 22
- Omalizumab - 41

Question 2

How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

Response:

- Adalimumab – Humira - 22
- Adalimumab Biosimilar - 49

- Bimekizumab - 2
- Certolizumab - 0
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 6
- Secukinumab - 13
- Ustekinumab - 0
- Ustekinumab Biosimilar - 0

Email: Foi.Team@Southerntrust.hscni.net